T1	CHEM 1047 1054	FARMEsc
#1	AnnotatorNotes T1	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T2	PROC 76 83	Placebo
#2	AnnotatorNotes T2	C0032042; Placebos; Therapeutic or Preventive Procedure
T3	DISO 99 118	Artritis Reumatoide
#3	AnnotatorNotes T3	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T4	CHEM 139 204	fármacos antireumaticos modificadores de la enfermedad sintéticos
#4	AnnotatorNotes T4	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T5	CHEM 1387 1393	FARMEb
T6	PROC 307 351	Estudio de fase 3, aleatorizado, doble ciego
T7	PROC 375 382	placebo
#5	AnnotatorNotes T7	C0032042; Placebos; Therapeutic or Preventive Procedure
T8	DISO 398 417	artritis reumatoide
#6	AnnotatorNotes T8	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T9	CHEM 475 541	fármacos antirreumáticos modificadores de la enfermedad sintéticos
#7	AnnotatorNotes T9	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T10	CHEM 558 565	FARMEsc
#8	AnnotatorNotes T10	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T11	DISO 641 660	Artritis Reumatoide
#9	AnnotatorNotes T11	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T12	DISO 662 664	AR
#10	AnnotatorNotes T12	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T13	DISO 691 710	Artritis Reumatoide
#11	AnnotatorNotes T13	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T14	DISO 712 714	AR
#12	AnnotatorNotes T14	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T15	PROC 813 824	Diagnóstico
#13	AnnotatorNotes T15	C0011900; Diagnosis; Diagnostic Procedure
T16	DISO 828 830	AR
#14	AnnotatorNotes T16	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T17	CHEM 999 1006	fármaco
#15	AnnotatorNotes T17	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T18	CHEM 1056 1059	MTX
#16	AnnotatorNotes T18	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T19	CHEM 1061 1074	sulfasalazina
#17	AnnotatorNotes T19	C0036078; sulfasalazine; Organic Chemical · Pharmacologic Substance
T20	CHEM 1076 1093	hidroxicloroquina
#18	AnnotatorNotes T20	C0020336; hydroxychloroquine; Organic Chemical · Pharmacologic Substance
T21	CHEM 1095 1105	cloroquina
#19	AnnotatorNotes T21	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T22	CHEM 1109 1120	leflunomida
#20	AnnotatorNotes T22	C0063041; leflunomide; Organic Chemical · Pharmacologic Substance
T23	DISO 1177 1187	enfermedad
#21	AnnotatorNotes T23	C0012634; Disease; Disease or Syndrome
T24	DISO 1200 1225	articulaciones inflamadas
#22	AnnotatorNotes T24	C0003864; Arthritis; Disease or Syndrome
T25	DISO 1252 1276	articulaciones dolorosas
#23	AnnotatorNotes T25	C0003862; Arthralgia; Sign or Symptom
T26	CHEM 1829 1835	FARMEb
T27	CHEM 221 228	FARMEsc
#24	AnnotatorNotes T27	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T28	CHEM 1535 1563	inhibidor de la Janus kinasa
T29	CHEM 1565 1568	JAK
#25	AnnotatorNotes T29	C0597721; Janus kinase; Amino Acid, Peptide, or Protein · Enzyme
T30	CHEM 1576 1587	tofacitinib
#26	AnnotatorNotes T30	C2930696; tofacitinib; Organic Chemical · Pharmacologic Substance
T31	DISO 1648 1671	artropatía inflamatoria
T32	DISO 1687 1689	AR
#27	AnnotatorNotes T32	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T33	DISO 1723 1753	síndrome de Sjogren secundario
#28	AnnotatorNotes T33	C0151450; Secondary Sjögren's syndrome; Disease or Syndrome
T34	PROC 1813 1824	tratamiento
#29	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	CHEM 64 71	ABT-494
#30	AnnotatorNotes T35	C4308782; ABT-494; Organic Chemical · Pharmacologic Substance
T36	CHEM 363 370	ABT-494
#31	AnnotatorNotes T36	C4308782; ABT-494; Organic Chemical · Pharmacologic Substance
T37	CHEM 272 279	FARMEsc
#32	AnnotatorNotes T37	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T38	CHEM 611 618	FARMEsc
#33	AnnotatorNotes T38	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T39	CHEM 879 886	FARMEsc
#34	AnnotatorNotes T39	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T40	PROC 980 1006	administración del fármaco
#35	AnnotatorNotes T40	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T41	ANAT 1200 1214	articulaciones
#36	AnnotatorNotes T41	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T42	ANAT 1252 1266	articulaciones
#37	AnnotatorNotes T42	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T43	CHEM 1589 1600	baricitinib
#38	AnnotatorNotes T43	C4044947; baricitinib; Organic Chemical · Pharmacologic Substance
T44	CHEM 1603 1613	filgotinib
#39	AnnotatorNotes T44	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T45	PROC 863 871	tratados
#40	AnnotatorNotes T45	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T46	Date 12 16	2015
T47	LIVB 87 94	sujetos
#41	AnnotatorNotes T47	C0681850; Study Subject; Group
T48	Dose 122 135	dosis estable
T50	LIVB 386 393	sujetos
#42	AnnotatorNotes T50	C0681850; Study Subject; Group
T51	Dose 454 471	una dosis estable
T53	LIVB 768 792	Adulto de cualquier sexo
#43	AnnotatorNotes T53	C0001675; Adult; Age Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T54	Age 794 810	mayor de 18 años
T55	Duration 839 848	≥ 3 meses
T56	Duration 895 904	≥ 3 meses
T57	Dose 922 939	una dosis estable
T58	Duration 948 959	≥ 4 semanas
T59	LIVB 1340 1347	sujetos
#44	AnnotatorNotes T59	C0681850; Study Subject; Group
T61	LIVB 1757 1764	Sujetos
#45	AnnotatorNotes T61	C0681850; Study Subject; Group
T62	LIVB 1855 1867	investigador
#46	AnnotatorNotes T62	C0035173; Research Personnel; Professional or Occupational Group
T64	LIVB 1454 1475	población del estudio
#47	AnnotatorNotes T64	C2348561; Study Population (group); Population Group
T49	DISO 183 193	enfermedad
#48	AnnotatorNotes T49	C0012634; Disease; Disease or Syndrome
T52	DISO 520 530	enfermedad
#49	AnnotatorNotes T52	C0012634; Disease; Disease or Syndrome
T60	Neg_cue 1672 1683	distinta de
T63	PROC 1304 1324	visitas de selección
#50	AnnotatorNotes T63	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T65	Quantifier_or_Qualifier 1327 1332	basal
#51	AnnotatorNotes T65	C1442488; Baseline; Quantitative Concept
A1	Population_data T53 Age
A2	Status T31 History_of
A3	Assertion T32 Negated
A4	Status T33 History_of
A5	Status T37 History_of
A6	Status T38 History_of
A7	Status T45 History_of
A8	Status T39 History_of
A9	Status T1 History_of
A10	Status T18 History_of
A11	Status T20 History_of
A12	Status T19 History_of
A13	Status T21 History_of
A14	Status T22 History_of
A15	Status T5 History_of
A16	Status T28 History_of
A18	Status T30 History_of
A19	Status T43 History_of
A20	Status T44 History_of
A21	Status T32 History_of
#52	AnnotatorNotes T6	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#53	AnnotatorNotes T28	C3854325; Janus kinase inhibitor; Pharmacologic Substance 
#54	AnnotatorNotes T31	C0003864; Arthritis; Disease or Syndrome
T66	Observation 580 608	respondido de forma adecuada
A22	Assertion T66 Negated
T67	Neg_cue 573 575	no
T68	Observation 241 269	respondido de forma adecuada
A23	Assertion T68 Negated
T69	Neg_cue 234 236	no
R1	Negation Arg1:T69 Arg2:T68	
R2	Negation Arg1:T67 Arg2:T66	
R3	Negation Arg1:T60 Arg2:T32	
R4	Experiences Arg1:T47 Arg2:T35	
R5	Experiences Arg1:T47 Arg2:T2	
R6	Experiences Arg1:T47 Arg2:T3	
R7	Experiences Arg1:T47 Arg2:T4	
R8	Has_Dose_or_Strength Arg1:T4 Arg2:T48	
R9	Experiences Arg1:T47 Arg2:T49	
R10	Before Arg1:T4 Arg2:T35	
R11	Before Arg1:T4 Arg2:T2	
R12	Experiences Arg1:T47 Arg2:T27	
R13	Before Arg1:T27 Arg2:T35	
R14	Before Arg1:T27 Arg2:T2	
R15	Overlap Arg1:T68 Arg2:T37	
R16	Experiences Arg1:T47 Arg2:T68	
R17	Experiences Arg1:T47 Arg2:T37	
R18	Before Arg1:T37 Arg2:T35	
R19	Before Arg1:T37 Arg2:T2	
#55	AnnotatorNotes T68	C1319171; Medication response; Finding
#56	AnnotatorNotes T66	C1319171; Medication response; Finding
R20	Overlap Arg1:T66 Arg2:T38	
R21	Experiences Arg1:T50 Arg2:T36	
R22	Experiences Arg1:T50 Arg2:T7	
R23	Experiences Arg1:T50 Arg2:T8	
R24	Experiences Arg1:T50 Arg2:T9	
R25	Experiences Arg1:T50 Arg2:T52	
R26	Experiences Arg1:T50 Arg2:T10	
R27	Experiences Arg1:T50 Arg2:T66	
R28	Experiences Arg1:T50 Arg2:T38	
T70	Quantifier_or_Qualifier 418 424	activa
#57	AnnotatorNotes T70	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R29	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T70	
T71	Quantifier_or_Qualifier 425 441	moderada a grave
#58	AnnotatorNotes T71	C1299393; Moderate to severe; Qualitative Concept
R30	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T71	
R31	Has_Dose_or_Strength Arg1:T9 Arg2:T51	
R32	Has_Dose_or_Strength Arg1:T10 Arg2:T51	
R33	Has_Dose_or_Strength Arg1:T27 Arg2:T48	
R34	Has_Dose_or_Strength Arg1:T37 Arg2:T48	
R35	Has_Dose_or_Strength Arg1:T38 Arg2:T51	
R36	Overlap Arg1:T9 Arg2:T66	
R37	Overlap Arg1:T10 Arg2:T66	
R38	Overlap Arg1:T4 Arg2:T68	
R39	Overlap Arg1:T27 Arg2:T68	
T72	Quantifier_or_Qualifier 723 739	moderada a grave
#59	AnnotatorNotes T72	C1299393; Moderate to severe; Qualitative Concept
R40	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T72	
R41	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T72	
T73	Quantifier_or_Qualifier 716 722	activa
#60	AnnotatorNotes T73	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R42	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T73	
R43	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T73	
R44	Has_Age Arg1:T53 Arg2:T54	
R45	Has_Duration_or_Interval Arg1:T16 Arg2:T55	
R46	Used_for Arg1:T39 Arg2:T45	
R47	Has_Duration_or_Interval Arg1:T39 Arg2:T56	
R48	Has_Dose_or_Strength Arg1:T39 Arg2:T57	
R51	Before Arg1:T45 Arg2:T40	
R50	Has_Duration_or_Interval Arg1:T57 Arg2:T58	
R49	Used_for Arg1:T17 Arg2:T40	
T74	Quantifier_or_Qualifier 1196 1199	≥ 6
R52	Location_of Arg1:T41 Arg2:T24	
R53	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T74	
R54	Location_of Arg1:T42 Arg2:T25	
T75	Quantifier_or_Qualifier 1248 1251	≥ 6
R55	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T75	
R56	Causes Arg1:T23 Arg2:T24	
R57	Causes Arg1:T23 Arg2:T25	
T76	PROC 1304 1311	visitas
#61	AnnotatorNotes T76	C1512346; Patient Visit; Health Care Activity
R61	Has_Quantifier_or_Qualifier Arg1:T76 Arg2:T65	
T77	Quantifier_or_Qualifier 1377 1386	máximo un
R65	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T77	
#62	AnnotatorNotes T26	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
R66	Used_for Arg1:T26 Arg2:T34	
#63	AnnotatorNotes T5	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
R67	Experiences Arg1:T59 Arg2:T5	
T78	CONC 1401 1410	incluirse
#64	AnnotatorNotes T78	C1512693; Inclusion; Qualitative Concept
T79	Quantifier_or_Qualifier 1433 1447	máximo del 20%
R69	Has_Quantifier_or_Qualifier Arg1:T64 Arg2:T79	
R70	Experiences Arg1:T64 Arg2:T5	
T80	CONC 1691 1702	Se permiten
T81	Observation 1787 1809	insuficiente respuesta
#65	AnnotatorNotes T81	C0858218; Inappropriate drug response; Finding
R71	Experiences Arg1:T61 Arg2:T81	
R72	Overlap Arg1:T81 Arg2:T34	
R73	Experiences Arg1:T61 Arg2:T34	
T82	CONC 1020 1031	Se permiten
R68	Before Arg1:T5 Arg2:T78	
R74	Before Arg1:T9 Arg2:T36	
R75	Before Arg1:T9 Arg2:T7	
R76	Before Arg1:T10 Arg2:T36	
R77	Before Arg1:T10 Arg2:T7	
R78	Before Arg1:T38 Arg2:T36	
R79	Before Arg1:T38 Arg2:T7	
R58	Overlap Arg1:T25 Arg2:T76	
R59	Overlap Arg1:T25 Arg2:T63	
R60	Overlap Arg1:T23 Arg2:T76	
R62	Overlap Arg1:T23 Arg2:T63	
R63	Overlap Arg1:T24 Arg2:T76	
R64	Overlap Arg1:T24 Arg2:T63	
A17	Experiencer T47 Patient
A24	Experiencer T50 Patient
A25	Experiencer T53 Patient
A26	Experiencer T59 Patient
A27	Experiencer T64 Patient
A28	Experiencer T61 Patient
A29	Experiencer T62 Other
